N. Maezaki et al.
FULL PAPER
a colorless oil. ee 89% (column: Daicel CHIRALPAK® AD-H, 3.88 (s, 3 H), 3.91 (s, 3 H), 5.44 (d, J = 7.3 Hz, 0.5 H), 5.53 (d, J
iPrOH/hexane = 98:2, flow rate: 1 mL/min, λ = 254 nm). [α]2D5
–21.2 (c = 0.72, CHCl3).
=
= 7.1 Hz, 0.5 H), 5.54 (d, J = 2.2 Hz, 1 H), 6.017 (br. s, 0.5 H),
6.024 (br. s, 0.5 H), 6.028 (br. s, 0.5 H), 6.043 (br. s, 0.5 H), 6.24
(d, J = 2.2 Hz, 1 H), 6.59 (dd, J = 7.8, 1.5 Hz, 0.5 H), 6.64 (d, J =
1.2 Hz, 0.5 H), 6.69 (s, 1 H), 6.70 (dd, J = 7.8, 1.2 Hz, 0.5 H), 6.73
(d, J = 1.5 Hz, 0.5 H), 6.87 (d, J = 7.8 Hz, 1 H) ppm. 13C NMR:
δ = 17.03 (0.5 C), 17.21 (0.5 C), 38.14 (0.5 C), 38.32 (0.5 C), 56.11,
60.85, 61.10 (0.5 C), 61.16 (0.5 C), 79.29 (0.5 C), 79.35 (0.5 C),
101.16 (0.5 C), 101.20 (0.5 C), 104.78 (0.5 C), 104.83 (0.5 C), 108.18
(0.5 C), 108.51 (0.5 C), 109.91 (0.5 C), 110.54 (0.5 C), 121.94,
122.72 (0.5 C), 123.31 (0.5 C), 127.12, 128.97, 130.03 (0.5 C),
130.06 (0.5 C), 141.06 (0.5 C), 141.14 (0.5 C), 141.83 (0.5 C), 146.94
(0.5 C), 147.04, 147.64 (0.5 C), 147.72 (0.5 C), 151.47, 152.90,
General Procedure for TIPS Deprotection
(1R,2S)-1-(3Ј,4,4Ј,5,5Ј,6-Hexamethoxybiphenyl-2-yl)-2-methyl-3-
methylenebutane-1,4-diol (20): Tetrabutylammonium fluoride (1 m
in THF, 1.54 mL, 1.54 mmol) was added to a solution of 19
(310 mg, 0.51 mmol) in THF (5 mL) at room temp. under Ar, and
the mixture was stirred for 2 h. The reaction was then quenched
with saturated aqueous NH4Cl, and the mixture was partitioned
between EtOAc and water. The organic phase was separated, and
the aqueous phase was extracted with EtOAc. The combined ex-
tracts were washed with saturated aqueous NH4Cl, water, and brine
prior to drying and solvent evaporation. The crude residue was
purified by chromatography on silica gel with hexane/EtOAc (1:2)
to give diol 20 (228 mg, quant.) as a colorless oil. [α]2D6 = –30.5 (c
= 0.54, CHCl3). 1H NMR: δ = 0.95 (d, J = 7.0 Hz, 3 H), 2.41 (qd,
J = 7.0, 2.6 Hz, 1 H), 3.69 (s, 3 H), 3.70 (d, J = 12.7 Hz, 1 H), 3.82
(d, J = 12.7 Hz, 1 H), 3.82 (s, 3 H), 3.86 (s, 3 H), 3.89 (s, 3 H),
3.90 (s, 3 H), 3.93 (s, 3 H), 4.60 (s, 1 H), 4.77 (d, J = 2.6 Hz, 1 H),
4.97 (s, 1 H), 6.44 (d, J = 1.7 Hz, 1 H), 6.47 (d, J = 1.7 Hz, 1 H),
7.02 (s, 1 H) ppm. 13C NMR: δ = 10.53, 43.21, 55.91, 56.02, 56.14,
60.71, 60.80, 61.18, 64.12, 72.32, 105.63, 106.65, 108.12, 113.12,
127.05, 131.85, 136.26, 136.85, 140.77, 150.77, 150.81, 152.30,
170.11 (0.5 C), 170.15 (0.5 C) ppm. IR (KBr): ν = 1767 cm–1. MS
˜
(FAB): m/z = 399 [M + H]+. HRMS (FAB): calcd. for C22H23O7
[M + H]+ 399.1444; found 399.1422.
(–)-Eupomatilone 1 (3): (–)-Eupomatilone 1 (3) was prepared in a
manner similar to that described for the preparation of (+)-eupom-
atilone 2 (1). Yield 85%. ee 88% (column: Daicel CHIRALPAK®
AD-H, iPrOH/hexane = 60:40, flow rate: 1 mL/min, λ = 254 nm).
1
Colorless oil. [α]2D5 = –0.77 (c = 0.80, CHCl3). H NMR: δ = 0.88
(d, J = 7.3 Hz, 3 H), 2.86–2.98 (m, 1 H), 3.84 (s, 3 H), 3.845 (s, 3
H), 3.847 (s, 3 H), 3.91 (s, 3 H), 5.44 (d, J = 7.6 Hz, 1 H), 5.53 (d,
J = 2.3 Hz, 1 H), 6.00 (s, 2 H), 6.25 (d, J = 2.3 Hz, 1 H), 6.33 (d,
J = 1.7 Hz, 1 H), 6.43 (d, J = 1.7 Hz, 1 H), 6.56 (br. s, 1 H) ppm.
13C NMR: δ = 16.42, 38.27, 56.09, 56.18, 59.98, 60.86, 79.26,
100.77, 101.37, 106.60, 107.61, 121.84, 127.37, 128.88, 130.97,
136.58, 137.26, 140.64, 140.89, 148.79, 152.99, 153.26, 170.07 ppm.
152.80, 152.95 ppm. IR (KBr): ν = 3450, 3070, 1583 cm–1. MS
˜
(FAB): m/z
= 471 [M +
Na]+. HRMS (FAB): calcd. for
C24H32O8Na [M + Na]+ 471.1995; found 471.1985.
General Procedure for TEMPO Oxidation
IR (KBr): ν = 1766, 1618, 1583 cm–1. MS (FAB): m/z = 429 [M +
˜
H]+. HRMS (FAB): calcd. for C23H25O8 [M + H]+ 429.1549; found
429.1556.
(+)-Eupomatilone
(TEMPO; 6.7 mg, 0.043 mmol) and PhI(OAc)2 (156 mg,
0.47 mmol) were added to solution of diol 20 (192 mg,
2
(1): 2,2,6,6-Tetramethyl-1-piperidinyloxy
a
Supporting Information (see footnote on the first page of this arti-
cle): Characterization data of synthetic intermediates of eupomati-
lone 1 and 5, and 1H and 13C NMR spectra of all new compounds.
0.43 mmol) in dry CH2Cl2 (2.2 mL) with stirring at room temp.
under Ar. After continued stirring at room temp. for 1 h, additional
PhI(OAc)2 (227 mg, 0.68 mmol) was added to the mixture. The en-
tire mixture was then stirred at room temp. for 3.5 h. Next, the
mixture was diluted with CHCl3, and the resulting solution was
stirred with saturated Na2S2O3. Then the organic phase was sepa-
rated, and the aqueous phase was extracted with CHCl3. The com-
bined organic extracts were washed with saturated NaHCO3 and
brine prior to drying over Na2SO4 and solvent evaporation. The
residue was purified by chromatography on silica gel with hexane/
EtOAc (2:1) to give (+)-eupomatilone 2 (1; 180 mg, 95%) as a pale
yellow oil. ee 89% (column: Daicel CHIRALPAK® AD-H,
Acknowledgments
This study was supported by a Grant-in-Aid for Scientific Research
(C) from the Japan Society for the Promotion of Science (grant
number 21590032) and the Osaka Ohtani University Research
Fund (Pharmaceutical Sciences).
iPrOH/hexane = 85:15, flow rate: 1 mL/min, λ = 254 nm). [α]2D3
=
[1] A. R. Carroll, W. C. Taylor, Aust. J. Chem. 1991, 44, 1705–
1714.
1
+12.0 (c = 0.60, CHCl3). H NMR: δ = 0.84 (d, J = 7.3 Hz, 3 H),
2.88 (qnt, J = 7.3, 2.2 Hz, 1 H), 3.70 (s, 3 H), 3.85 (s, 3 H), 3.86
(s, 3 H), 3.88 (s, 3 H), 3.92 (s, 6 H), 5.52 (d, J = 7.3 Hz, 1 H), 5.55
(d, J = 2.2 Hz, 1 H), 6.26 (d, J = 2.2 Hz, 1 H), 6.37 (d, J = 1.7 Hz,
1 H), 6.46 (d, J = 1.7 Hz, 1 H), 6.69 (s, 1 H) ppm. 13C NMR: δ =
16.86, 38.31, 56.12, 56.16, 56.25, 60.88, 60.92, 61.37, 79.26, 104.86,
106.42, 107.42, 122.07, 127.64, 129.86, 131.02, 137.28, 140.90,
[2] S. Mitra, S. R. Gurrala, R. S. Coleman, J. Org. Chem. 2007,
72, 8724–8736.
[3] a) B. B. Patel, T. G. Waddell, R. M. Pagni, Fitoterapia 2001,
72, 511–515; b) H. M. R. Hoffmann, J. Rabe, Angew. Chem.
1985, 97, 96–112; Angew. Chem. Int. Ed. Engl. 1985, 24, 94–
110; c) S. M. Kupchan, G. Bondesson, A. P. Davies, J. Med.
Chem. 1971, 14, 1147–1152; d) S. M. Kupchan, D. C. Fessler,
M. A. Eakin, T. J. Giacobbe, Science 1970, 168, 376–378.
[4] For synthesis of congeners of eupomatilone 2, see: a) J. B.
Johnson, E. A. Bercot, C. M. Williams, T. Rovis, Angew. Chem.
2007, 119, 4598–4602; Angew. Chem. Int. Ed. 2007, 46, 4514–
4518; b) M. K. Gurjar, B. Karumudi, C. V. Ramana, J. Org.
Chem. 2005, 70, 9658–9661; c) M. P. Rainka, J. E. Milne, S. L.
Buchwald, Angew. Chem. 2005, 117, 6333–6336; Angew. Chem.
Int. Ed. 2005, 44, 6177–6180; d) S. H. Yu, M. J. Ferguson, R.
McDonald, D. G. Hall, J. Am. Chem. Soc. 2005, 127, 12808–
12809; e) J. M. Hutchison, S.-P. Hong, M. C. McIntosh, J. Org.
Chem. 2004, 69, 4185–4191; f) R. S. Coleman, S. R. Gurrala,
Org. Lett. 2004, 6, 4025–4028; g) M. K. Gurjar, J. Cherian,
141.90, 151.25, 152.98, 153.06, 153.24, 170.14 ppm. IR (KBr): ν =
˜
3097, 1767, 1664, 1592 cm–1. MS (FAB): m/z = 445 [M + H]+.
HRMS (FAB): calcd. for C24H29O8 [M + H]+ 445.1862; found
445.1853.
(+)-Eupomatilone 5 (2): (+)-Eupomatilone 5 (2) was prepared in a
manner similar to that described for the preparation of (+)-eupom-
atilone 2 (1). Yield 90%. ee 91% (column: Daicel CHIRALPAK®
AD-H, iPrOH/hexane = 80:20, flow rate: 1 mL/min, λ = 254 nm).
Colorless oil. 1:1 Mixture of rotamers. [α]2D4 = +26.4 (c = 1.04,
CHCl3). 1H NMR: δ = 0.80 (d, J = 7.6 Hz, 1.5 H), 0.82 (d, J =
7.3 Hz, 1.5 H), 2.81–2.92 (m, 1 H), 3.64 (s, 1.5 H), 3.65 (s, 1.5 H),
726
www.eurjoc.org
© 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2013, 721–727